TOP TEN perturbations for NM_000265 (Homo sapiens)

Organism: Homo sapiens
Gene: NM_000265
Selected probe(set): 214084_x_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array

Expression of NM_000265 (214084_x_at) across 5339 perturbations tested by GENEVESTIGATOR:

B-CLL study 11 (DMSO) / vehicle (DMSO) treated normal T-cell sample

Relative Expression (log2-ratio):4.0581493
Number of Samples:4 / 4
Experimental B-CLL study 11 (DMSO)
Peripheral blood mononuclear cells (PBMCs) obtained from chronic lymphocytic leukemia (CLL) patients and in vitro treated with vehicle (DMSO) for 4 hours. PBMCs? samples contained 90% CD19+ CD5+ B lineage CLL cells (B-CLL). Inclusion criteria: untreated CLL patients or at least 1 month after chemotherapy. Exclusion criteria: patients with active infections or other serious medical conditions or with white blood cell (WBC) counts of 15,000/l.
Control vehicle (DMSO) treated normal T-cell sample
MACS purified T-cells from healthy donor peripheral blood treated with vehicle (DMSO) for 4 hours.

Langerhans cell histiocytosis study 1 / normal epidermal Langerhans cell sample

Relative Expression (log2-ratio):3.9946413
Number of Samples:7 / 3
Experimental Langerhans cell histiocytosis study 1
Langerhans cell histiocytes (LCH) were isolated from LCH lesions of patients undergoing surgery. All patients had single system disease, five patients had bone lesion, one had skin lesion and one had mucosal manifestation. Langerhans cells histiocytes were purified by FACS as CD1a+ / CD270 + population with > 95% purity.
Control normal epidermal Langerhans cell sample
Normal epidermal Langerhans cells were isolated from skin of healthy adult donors. Single cells were isolated by collagenase digestion from epidermal sheets and CD1a - expressing cells were isolated by FACS purification. Gene-chips were further analyzed for transcripts of potentially contaminating cells - no transcripts for CD3? (T cell), CD19 (B cell) or Desmogleins 1-4 (keratinocytes) were detected, confirming purity of sorted cells.

PMA study 2 / mock treated MONO-MAC-6 cell sample

Relative Expression (log2-ratio):3.9169712
Number of Samples:3 / 2
Experimental PMA study 2
MONO-MAC-6 (MM6) cells were treated with 10 ng/ml phorbol 12-myristate 13-acetate (PMA). ATC code:---
Control mock treated MONO-MAC-6 cell sample
MONO-MAC-6 (MM6) cells mock treated.

AML study 1 (t(15;17)(q22;q11-12)) / normal bone marrow sample

Relative Expression (log2-ratio):-3.7842064
Number of Samples:36 / 74
Experimental AML study 1 (t(15;17)(q22;q11-12))
Bone marrow samples of patients with acute promyelocytic leukemia [subtype of acute myeloid leukemia (AML)] with genetic aberration (t(15;17)(q22;q11-12)/PML-RAR? and variations).
Control normal bone marrow sample
Non-leukemic and healthy bone marrow sample.

LPS study 4 / mock treated MONO-MAC-6 cell sample

Relative Expression (log2-ratio):3.4284115
Number of Samples:2 / 2
Experimental LPS study 4
MONO-MAC-6 (MM6) cells were treated with 10 ng/ml lipopolysaccharide (LPS). ATC code:---
Control mock treated MONO-MAC-6 cell sample
MONO-MAC-6 (MM6) cells mock treated.

cutaneous sarcoidosis study 1 (lesional) / normal skin tissue

Relative Expression (log2-ratio):3.3415022
Number of Samples:13 / 5
Experimental cutaneous sarcoidosis study 1 (lesional)
Lesional skin biopsies from patients with acute cutaneous sarcoidosis.
Control normal skin tissue
Skin biopsy samples from healthy control subjects.

EBNA2 overexpr. study 1 (24h) / NOTCH1-IC overexpr. study 2 (24h)

Relative Expression (log2-ratio):-3.2816133
Number of Samples:3 / 3
Experimental EBNA2 overexpr. study 1 (24h)
EREB2-5 cell line stably transfected with the chimeric Epstein-Barr virus-encoded nuclear antigen 2 (EBNA2) and control expression plasmid coding for bacterial chloramphenicol acetyltransferase (CAT) gene and . CAT was used as a negative control. Briefly, before the CAT and EBNA2 induction, cells were maintained in RPMI media and deprived of estrogen for 3 days before doxycycline and estrogen was added. Expression of EBNA2 was induced after addition of estrogen and expression of CAT was induced by the addition of doxycycline to a final concentration of 100 ng/mL medium. Doxycycline induced cells were harvested 24 hours after induction. Because EBNA2 is essential for the proliferation of EBV-infected cells, EREB2-5 cells grow only in the presence of estrogen. Before the preparation of RNA, NGFR cells were purified by MACS separation to enrich the cells with a transcriptional response to doxycycline.
Control NOTCH1-IC overexpr. study 2 (24h)
EREB2-5 cell line stably transfected with expression plasmid coding for intracellular domain of NOTCH1 (NOTCH1-IC). The stably transfected cells were maintained in RPMI media and deprived of estrogen for 3 days, before doxycycline was added. Expression of NOTCH1-IC was induced by the addition of doxycycline to a final concentration of 100 ng/mL medium. Doxycycline induced cells were harvested 24 hours after induction. Estrogen withdrawal leads to the inactivation of EBNA2, resulting in cell cycle arrest. Before the preparation of RNA, NGFR cells were purified by MACS separation to enrich the cells with a transcriptional response to doxycycline.

E. coli study 2 / unstimulated, normal monocyte-derived macrophage sample

Relative Expression (log2-ratio):3.2206116
Number of Samples:5 / 7
Experimental E. coli study 2
Monocyte-derived macrophage samples derived from healthy control subjects cultured for 4 hours with 2.5 ? 105 heat-killed E. coli.
Control unstimulated, normal monocyte-derived macrophage sample
Monocyte-derived macrophage samples derived from healthy control subjects cultured for 4 hours unstimulated.

IL-4; GM-CSF study 1 (intermediate) / untreated monocyte sample

Relative Expression (log2-ratio):-3.212369
Number of Samples:7 / 12
Experimental IL-4; GM-CSF study 1 (intermediate)
Monocytes, cultured with vehicle (DMSO/ethanol) and 500 U/ml IL-4 and 800 U/ml GM-CSF for 24 hours.
Control untreated monocyte sample
Freshly isolated human monocytes from healthy donors.

cutaneous sarcoidosis study 1 (lesional) / cutaneous sarcoidosis study 1 (non-lesional)

Relative Expression (log2-ratio):3.1567736
Number of Samples:13 / 9
Experimental cutaneous sarcoidosis study 1 (lesional)
Lesional skin biopsies from patients with acute cutaneous sarcoidosis.
Control cutaneous sarcoidosis study 1 (non-lesional)
Non-lesional skin biopsies from patients with acute cutaneous sarcoidosis.